Filters
In children, dehiscence, severe recurrent ventral curvature, and urethral strictures all aggravate the risk of reoperation after primary hypospadias repair, a recent study.
In the treatment of vasculogenic erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy (Li-ESWT) is safe and effective for some patients, particularly those with mild-to-moderate ED, a study suggests.
Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.
In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).
Despite high rates of reoperation, most children on sacral neuromodulation (SNM) devices either continue to use these tools or experience symptom improvements enough to permit device removal in the moderate term, according to a new study.
Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.
Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.
Intravesical administration of the IL-15RαFc* superagonist N-803 with BCG** demonstrated a strong efficacy and an excellent safety and tolerability profile in patients with BCG-unresponsive high-grade NMIBC*** carcinoma in situ, according to an interim analysis presented at ASCO GU 2021.
The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.
A novel polygenic hazard score adapted to different genetic ancestries can be used for reliable risk-stratification among prostate cancer patients across multiple ethnicities, a recent study has found.
